| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H28ClN3O5S |
| Molecular Weight | 445.961 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)NCCN1CCC(CCC(=O)C2=C3OCCOC3=C(N)C(Cl)=C2)CC1
InChI
InChIKey=NBUGBCTWXCXBQD-UHFFFAOYSA-N
InChI=1S/C19H28ClN3O5S/c1-29(25,26)22-6-9-23-7-4-13(5-8-23)2-3-16(24)14-12-15(20)17(21)19-18(14)27-10-11-28-19/h12-13,22H,2-11,21H2,1H3
| Molecular Formula | C19H28ClN3O5S |
| Molecular Weight | 445.961 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulamserod is a methanesulfonamide derivative patented by British multinational pharmaceutical company GlaxoSmithKline as 5-HT4 receptor antagonist, with antiarrhythmic activities for the treatment of the certain cardiovascular condition. 5-HT4 receptor blockade could have antiarrhythmic effects by decreasing intracellular Ca2+ concentration and delayed rectifier potassium current and prolonging atrial refractory period. In preclinical models, Sulamserod prolongs mean atrial effective refractory period and wavelength, reduces the dispersion of effective refractory period, and minimally slows conduction velocity in pigs.
Approval Year
PubMed
Patents
|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 2 of 2 entries
